Group 1: Investment Opportunities - The article highlights three dividend growth stocks that are currently undervalued, with share prices down between 19% and 26% from their highs, presenting a buying opportunity for investors [2][3] Group 2: Zoetis - Zoetis is a leading company in the animal healthcare industry, offering a variety of products including medicines and vaccines, and has outperformed the S&P 500 since its IPO in 2013 [3][4] - The company's valuation peaked at an average of 47 times free cash flow (FCF) over the last decade, but has now adjusted to a more reasonable 31 times FCF, with a dividend yield of 1.2% [4][5] - Zoetis has a return on invested capital (ROIC) of 22%, indicating strong growth potential through new product introductions and lifecycle innovations [7] - The company has achieved a 28% growth in FCF and an 18% increase in dividend payments annually over the last decade, making it a strong compounder [8] - Recent sales growth in parasiticides, dermatology, and pain products exceeding 10% suggests continued rewards for dividend investors [9] Group 3: Pool Corp. - Pool Corp. is the largest distributor of pool products globally and has seen significant growth since its IPO in 1995, but its share price has stagnated recently due to economic factors [11] - The company generates 64% of its sales from non-discretionary maintenance and repair, providing stability amid cyclical downturns [12] - Despite challenges, Pool Corp. generated nearly $500 million in FCF last year and has utilized this to repurchase shares, with its stock down 23% from year-long highs [13] - The company has an average ROIC of 18%, demonstrating its ability to navigate economic cycles profitably [14] - Pool Corp. currently offers a 1.6% dividend yield, the highest since 2012, with only 38% of FCF used for dividends, indicating potential for future growth [15] Group 4: Old Dominion Freight Line - Old Dominion Freight Line specializes in less-than-truckload (LTL) hauling and has been a strong performer since its IPO in 1991, though it is also subject to cyclical fluctuations [16][18] - The company has experienced a 26% drop in stock price due to a freight industry recession and weak industrial shipments [18] - Old Dominion boasts a leading ROIC, allowing it to gain market share and repurchase shares during economic downturns [20] - The company has reduced its share count by more than one-sixth over the last decade, and while its dividend yield is currently 0.6%, it has grown by 33% over the past five years, utilizing only 27% of FCF [21]

Group 1: Zoetis - Zoetis is a leading animal health company with a diverse portfolio, including 15 products generating over $100 million in annual sales, and has achieved a compound annual growth rate of 8% from 2014 to 2023, outperforming the industry average of 5% [4] - Despite facing competition, particularly with recent drug approvals challenging its growth driver Apoquel, Zoetis has a strong track record of innovation and continues to launch new products like Solensia and Librela, which treat osteoarthritis pain in pets [5][6] - The company benefits from long-term trends such as the growing pet population and increased demand for protein sources due to human population growth, positioning it well for future growth [7][8] - Zoetis has a solid dividend program with a forward yield of 1.3% and has increased its payouts by 502% over the past decade, maintaining a conservative payout ratio of 31.6%, allowing for potential future increases [9] Group 2: Eli Lilly - Eli Lilly has seen significant growth in revenue and earnings, with a 45% year-over-year increase in the first quarter, reaching $12.7 billion, and has doubled its dividends over the past five years [10] - The company has a diversified portfolio with blockbuster medicines in various therapeutic areas, including immunology and oncology, and a promising pipeline with products like Kisunla for Alzheimer's disease, which could generate over $1 billion in annual sales [11][12] - Despite a low forward yield of 0.8%, Eli Lilly's solid track record and a modest cash payout ratio of 44% indicate its attractiveness as a buy-and-hold option for dividend investors [13]

Core Viewpoint - Zoetis is recognized as a leader in a niche industry and has demonstrated consistent revenue growth despite market challenges [1] Company Analysis - The company has maintained a beneficial long position in its shares, indicating confidence in its future performance [1] Industry Context - The niche industry in which Zoetis operates continues to show resilience, contributing to the company's ability to grow revenue [1]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Zoetis (ZTS), and emphasizes the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank for making informed investment decisions [1][5][10]. Brokerage Recommendations for Zoetis - Zoetis has an average brokerage recommendation (ABR) of 1.26, indicating a consensus between Strong Buy and Buy, based on 17 brokerage firms [2]. - Out of the 17 recommendations, 14 are Strong Buy and 1 is Buy, which accounts for 82.4% and 5.9% of all recommendations respectively [2]. Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the best price increase potential [5]. - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, often issuing five "Strong Buy" recommendations for every "Strong Sell" [6][10]. - The interests of brokerage firms may not align with those of retail investors, leading to potential misguidance regarding stock price movements [7]. Zacks Rank as an Alternative - The Zacks Rank is presented as a more effective tool for predicting stock price performance, categorizing stocks from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) [8]. - Unlike the ABR, the Zacks Rank is based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [11]. - The Zacks Rank is updated more frequently than the ABR, making it a timely indicator for future stock prices [12]. Current Performance of Zoetis - The Zacks Consensus Estimate for Zoetis remains unchanged at $6.26, suggesting steady analyst views on the company's earnings prospects [13]. - Due to the recent changes in consensus estimates and other related factors, Zoetis holds a Zacks Rank 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [14].

Group 1 - Phibro Animal Health (NASDAQ: PAHC) announced a significant acquisition from Zoetis (ZTS) aimed at driving business momentum [1] - The investment group "Value In Corporate Events" focuses on identifying opportunities in IPOs, mergers & acquisitions, earnings reports, and corporate capital allocation [1] - The service covers approximately 10 major events monthly to find optimal investment opportunities [1]

Company Performance - Zoetis (ZTS) closed at $155.06, reflecting a -4.09% change from the previous day, underperforming the S&P 500 which had a daily loss of 0.03% [1] - The stock has decreased by 1.21% over the past month, while the Medical sector gained 1.25% and the S&P 500 increased by 0.6% [1] Upcoming Financial Results - Zoetis is expected to report an EPS of $1.61, indicating a 3.21% increase from the same quarter last year, with projected revenue of $2.4 billion, a 1.67% rise from the previous year [2] - For the full year, earnings are projected at $6.26 per share and revenue at $9.49 billion, representing increases of +5.74% and +2.53% respectively from the prior year [3] Analyst Estimates and Rankings - Recent changes in analyst estimates for Zoetis are crucial as they reflect optimism about the business and profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Zoetis at 3 (Hold) [5] Valuation Metrics - Zoetis has a Forward P/E ratio of 25.85, which is a premium compared to the industry average Forward P/E of 16.43 [6] - The company also has a PEG ratio of 2.68, while the Medical - Drugs industry average PEG ratio is 1.67 [6] Industry Context - The Medical - Drugs industry, part of the Medical sector, holds a Zacks Industry Rank of 79, placing it in the top 33% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Overview - Zoetis has over 70 years of experience in the animal health industry [4] - The company's annual revenue is $9.3 billion [4] - Zoetis has a global presence with operations in over 100 countries [4] - Companion animal products account for 68% of the company's revenue [4] - Livestock products account for 31% of the company's revenue [4] - Client Supply Services and Human Health represent 1% of total 2024 revenue [4] Market Position and Growth - The company has consistently grown faster than the animal health market [19] - Zoetis has experienced an 8% revenue CAGR since its IPO in 2013, compared to 5% for the animal health industry [21] - Zoetis U S Companion Animal revenue has a 91% correlation to growth in clinic revenue [26] - Zoetis U S Companion Animal revenue has a 12% correlation to growth in clinic visits [27] Future Market Growth - The animal health market is expected to grow from ~$48 billion in 2023 to ~$60-70 billion in 2028, and ~$75-85 billion in 2033 [33] - This represents a 6% CAGR to 2028 and a 4% CAGR from 2028 to 2033 [33]

Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market engagement, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service aims to help investors become more informed and confident in their investment decisions [1] Group 2: Zacks Style Scores - Zacks Style Scores are indicators designed to assist investors in selecting stocks with the potential to outperform the market within a 30-day timeframe, rated from A to F based on value, growth, and momentum characteristics [2] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Group 3: Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated 1 and 2, which can be overwhelming for investors, highlighting the importance of Style Scores in stock selection [9] Group 4: Stock Highlight - Zoetis Inc. (ZTS) - Zoetis Inc., based in Parsippany, NJ, specializes in animal health products and was spun off from Pfizer, trading on the NYSE since February 1, 2013 [12] - The company serves both livestock and companion animals across various product categories, including parasiticides, vaccines, and anti-infectives [12] - Zoetis holds a 3 (Hold) rating on the Zacks Rank with a VGM Score of B, and its shares have increased by 0.8% over the past four weeks [13] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate rising by $0.18 to $6.26 per share for fiscal 2025, and it boasts an average earnings surprise of 5.2% [13][14]

Core Viewpoint - Long-term investors can achieve significant wealth through steady growth and dividend increases, despite market volatility [1][2] Group 1: Market Insights - Market fluctuations are normal and can be leveraged as opportunities to invest in long-term growth stocks that consistently pay and increase dividends [2] - The U.S. healthcare industry, accounting for over 17% of the economy, presents substantial growth potential with several healthcare stocks demonstrating impressive performance [2] Group 2: Company Profiles - **Zoetis**: Specializes in animal healthcare with $9.3 billion in annual sales, has raised dividends for 12 consecutive years, and is expected to grow earnings by 10% annually [5][6] - **Johnson & Johnson**: A healthcare conglomerate with a 63-year dividend increase streak, current dividend yield of 3.3%, and expected earnings growth of 8% annually [7][9] - **Abbott Laboratories**: A Dividend King with over 50 years of dividend increases, currently yielding 1.8%, and expected earnings growth of 9% annually [10][11] - **Stryker Corp.**: Focuses on orthopedic devices and has a 32-year dividend growth streak, with an estimated earnings growth of almost 10% annually [12][13] - **Medtronic**: Develops medical devices with a 3.2% starting yield and 47 consecutive years of dividend increases, expected earnings growth of over 5% annually [14][15]

Core Insights - Zoetis (ZTS) has seen a 12.5% increase in share price over the past month, indicating strong market performance in the animal health sector [1] - The company operates across seven major product categories and serves eight core species, including both livestock and companion animals [1] Product Performance - Strong growth is attributed to Zoetis' companion animal portfolio, with key products like Apoquel, Cytopoint, and newer offerings such as Simparica and ProHeart 12 driving sales [3] - Recent FDA approvals for Apoquel Chewable and expanded indications for Simparica Trio are expected to enhance demand further [3] International Expansion - Zoetis is expanding its international presence, with products like Rimadyl approved in China and strong uptake of monoclonal antibody therapies for osteoarthritis pain in pets [4] Strategic Acquisitions - The company has been actively acquiring businesses to strengthen its market position, including the acquisition of PetMedix Ltd. and adivo GmbH, which focus on antibody-based therapeutics for companion animals [6] Technological Advancements - In early 2024, Zoetis enhanced its Vetscan Imagyst diagnostics platform with AI capabilities for urine testing and lymph node screening, improving in-clinic diagnostic capabilities [7] Shareholder Value - Zoetis has consistently increased dividends, with a 16% increase in the third quarter of 2025 compared to 2024, making it an attractive option for investors [8] Stock Performance and Valuation - Year-to-date, Zoetis shares have gained 3.5%, underperforming the industry average of 10.4%, but still outperforming the sector and S&P 500 [9] - The stock is currently trading at a premium valuation compared to the industry, but strong fundamentals suggest potential for lucrative returns [12] Earnings Estimates - The Zacks Consensus Estimate for Zoetis' 2025 earnings per share has risen from $6.08 to $6.26, with 2026 estimates increasing from $6.65 to $6.79, indicating a positive outlook for growth [15]